Lead Product(s): Tofacitinib Citrate
Therapeutic Area: Immunology Product Name: Xeljanz
Highest Development Status: Phase IV Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2021
The co-primary endpoints of this study were non-inferiority of tofacitinib compared to TNFi in regard to major adverse cardiovascular events (MACE) and malignancies (excluding non-melanoma skin cancer (NMSC)).
Lead Product(s): Teprotumumab,rHuPH20
Therapeutic Area: Immunology Product Name: Tepezza
Highest Development Status: Phase IV Product Type: Large molecule
Partner/Sponsor/Collaborator: Horizon Therapeutics
Deal Size: $190.0 million Upfront Cash: $30.0 million
Deal Type: Collaboration November 23, 2020
Horizon intends to use ENHANZE® to develop a SC formulation of TEPEZZA (teprotumumab-trbw), indicated for the treatment of Thyroid Eye Disease.